Kenneth Tew to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications Kenneth Tew has written about Drug Screening Assays, Antitumor.
Connection Strength
0.338
-
Pharmacology of ME-344, a novel cytotoxic isoflavone. Adv Cancer Res. 2019; 142:187-207.
Score: 0.155
-
The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J Pharmacol Exp Ther. 2000 Aug; 294(2):480-7.
Score: 0.043
-
Cellular response to a glutathione S-transferase P1-1 activated prodrug. Mol Pharmacol. 2000 Jul; 58(1):167-74.
Score: 0.042
-
Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol Ther. 1992 Dec; 56(3):323-39.
Score: 0.025
-
Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992 Aug 15; 52(16):4433-40.
Score: 0.025
-
Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036. Anticancer Res. 1989 Nov-Dec; 9(6):1617-22.
Score: 0.020
-
PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J Med Chem. 2006 Feb 09; 49(3):1157-64.
Score: 0.016
-
Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003 Aug; 64(2):382-94.
Score: 0.013